Get the Daily Brief
Latest Biotech News
AI Accelerates Drug Discovery: Eli Lilly Opens TuneLab Platform to Biotechs
Eli Lilly launched TuneLab, an AI platform granting biotech companies access to predictive models trained on Lilly’s extensive drug discovery data. This federated learning system protects...
Massive Gene and Protein Discoveries: Atlas Blue Butterfly Genome and Neuronal Lipid Metabolism Links
Researchers sequenced the genome of Polyommatus atlantica, the Atlas blue butterfly, identifying it as having the highest chromosome count among multicellular organisms due to chromosome...
New Diagnostic and Monitoring Advances in Lung and Prostate Cancer
University College London and collaborators demonstrated a faster, cost-effective MRI scan for prostate cancer diagnosis matching current standards. The National Cancer Center of China revealed...
Groundbreaking Long-Term CHO Cell Stability Prediction Model Developed by MIT
MIT scientists created the first publicly available artificial intelligence model predicting long-term stability of Chinese Hamster Ovary (CHO) cell lines over 72 passages, meeting FDA stability...
Emerging Trends in Immunotherapy and Targeted Lung Cancer Therapies
New clinical data highlight immunotherapy advances including Ideaya and Hengrui’s DLL3-targeting ADC IDE-849 showing promise in small-cell lung cancer. BioNTech’s bispecific pumitamig demonstrated...
Digital Innovations and New Models in Clinical Trials and Biotech Partnerships
City of Hope launched a national clinical trials model to accelerate access to emerging cancer therapies. Belgian bioinformatics firm Aspect Analytics raised €10 million to enhance spatial biology...
Novartis Expands Cardiovascular Pipeline: $1.4B Tourmaline Acquisition
Novartis has acquired Tourmaline Bio for $1.4 billion, gaining full rights to pacibekitug, an anti-IL-6 monoclonal antibody targeting atherosclerotic cardiovascular disease (ASCVD). Licensed...
Immunotherapy Breakthroughs in Lung and Small Cell Cancers
New clinical data highlight advancements in immunotherapy for lung cancers. BioNTech and Bristol Myers Squibb reported promising Phase 2 results combining PD-L1xVEGF dual-action drug pumitamig...
AI Platforms Drive Drug Discovery and Diagnostics Innovation
Eli Lilly launched TuneLab, an AI platform granting early-stage biotechs access to its sophisticated drug discovery models in exchange for data contributions. This initiative, part of Lilly’s...
Rapport Therapeutics’ Seizure Drug RAP-219 Surpasses Expectations
Rapport Therapeutics reported robust Phase IIa data for RAP-219, a TARPγ8-specific AMPAR negative allosteric modulator targeting drug-resistant focal onset seizures. The open-label study showed a...
Noa Therapeutics Advances Chronic Inflammatory Disease Pipeline with NEA Grant
Toronto-based Noa Therapeutics, pioneering biased engagement of the aryl hydrocarbon receptor (AhR), secured a Catalyst Research Grant from the National Eczema Association to study its lead...
Single-Cell Sequencing Trial Targets Myelodysplastic Syndromes Diagnostic Improvement
Researchers at the Weizmann Institute of Science initiated the PERIBLOOD clinical trial, enrolling 1,500 patients globally to evaluate single-cell sequencing utility in diagnosing myelodysplastic...
Cancer Therapy Innovation: Antibody–Bottlebrush Prodrugs and Immune Checkpoint Inhibitors
Nature Biotechnology published advancements in targeted cancer therapies, including antibody–bottlebrush prodrugs that offer expanded payload flexibility and improved delivery over traditional...
AI-Powered Environmental and Biological Monitoring Expands Frontiers
Innovations in AI and sensing technologies are revolutionizing environmental and biological surveillance. Researchers developed a self-powered microfluidic sensor detecting toxic amines in water...
Novel Diagnostics and Biomarkers in Alzheimer’s and Cancer Care
UC San Diego researchers identified blood biomarkers linked to cognitive decline in Hispanic/Latino adults, paving the way for a simple test for early Alzheimer's detection. Additionally, spatial...
Novartis Bolsters Cardiovascular Pipeline with $1.4B Tourmaline Bio Buy
Novartis has agreed to acquire Tourmaline Bio for approximately $1.4 billion, securing exclusive rights to pacibekitug, a promising anti-IL-6 monoclonal antibody aimed at tackling atherosclerotic...
Rapport’s Anti-Seizure Drug Surges on Phase II Success
Rapport Therapeutics reported robust Phase IIa data for RAP-219, an experimental drug targeting TARPγ8-specific AMPA receptors, showing a 78% median reduction in clinical seizures in patients with...
New FDA Approval for Johnson & Johnson’s Bladder Cancer Treatment Inlexzo
Johnson & Johnson secured FDA approval for Inlexzo, an intravesical gemcitabine delivery system for treatment of Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer...
Alzinova Advances Alzheimer’s Vaccine Candidate ALZ-101 to Phase II
Swedish biopharmaceutical company Alzinova received FDA clearance to begin Phase II clinical trials of ALZ-101, a vaccine targeting toxic amyloid-beta oligomers in Alzheimer’s disease. Following...
Eli Lilly Opens AI Drug Discovery Models to Biotech Partners via TuneLab
Eli Lilly launched TuneLab, an innovative AI platform providing early-stage biotech firms access to Lilly’s proprietary drug discovery machine learning models. Participating companies contribute...